Infertility

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Retrieved on: 
Thursday, March 21, 2024
ART, Obstetrics, Fireside, Gynaecology, Infertility, Case Western Reserve University, IVF, Climate, University, Woman, Reproductive biology, FDA

Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Retrieved on: 
Wednesday, March 20, 2024
Infertility, TMSC, Pregnancy rate, IVF, IUI, Pregnancy, Fertilisation, Woman, Male, Safety, Literature, FDA, ICSI, Insemination, Physician, Birth control

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847). The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed, engineered to enhance fertilization by precisely delivering sperm into the fallopian tube, the site of conception, demonstrated 24% of women became pregnant after FemaSeed with severe male factor (1 million to 20 million total motile sperm count (TMSC)). In contrast, a 6.7% pregnancy rate by cycle was described in the literature for intrauterine insemination (IUI) with male factor (greater than 1 million TMSC).1 Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The poor IUI pregnancy rates for this infertility segment usually necessitates assisted reproductive approaches, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points: 
  • The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility.
  • “These impressive topline results for our now FDA-cleared FemaSeed, demonstrate significant progress in the treatment of infertility, while confirming its safety profile.
  • “The pivotal trial amassed substantial prospective data in support of the safety and efficacy of FemaSeed as a groundbreaking advancement in artificial insemination.
  • The pivotal trial was concluded prior to completing full enrollment due to Femasys receiving FDA clearance for FemaSeed under the 510(k) pathway in September 2023.

TLI Investigator Dr. Wei Yan Named Editor-in-Chief of the Andrology Journal

Retrieved on: 
Monday, March 18, 2024
Reproduction, Lundquist, Managing editor, Infertility, SSR, Male, Social media, Research, Fertility, Doctor of Philosophy, MD, Biology of Reproduction, Society, ELife, Biology, Reproductive medicine, UCLA, Management

Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.

Key Points: 
  • Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.
  • With over 160 peer-reviewed publications and numerous awards, Dr. Yan is a committed researcher and educator.
  • Dr. Yan's vision for Andrology is to enhance its global influence and implement innovative strategies.
  • His plans include prioritizing cutting-edge reviews, rewarding high-quality contributions, and fostering the next generation of researchers through the Trainee Reviewer Program.

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

Retrieved on: 
Wednesday, March 13, 2024
ART, Obstetrics, Fireside, Gynaecology, Infertility, Case Western Reserve University, IVF, Climate, University, Woman, Reproductive biology, FDA

ATLANTA, March 13, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces it will participate in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Health, Medical Devices, Stem Cells, Genetics, General Health, Pharmaceutical, Biotechnology, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Research, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Prudential Financial introduces new workplace insurance benefits that help support mental health and growing families

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Mental Health, Health, Insurance, Health Insurance, Human Resources, Finance, PRU, Substance abuse, Infertility, Prudential Financial, Prudential, Mental health, Prenatal care, Hospice and palliative medicine, Anxiety, DSM-IV codes, Hospital, Multimedia, Family, Group insurance, Health insurance

Prudential Financial, Inc. ( NYSE: PRU ) has introduced new voluntary workplace insurance offerings that help support family building and mental health, including benefits that cover fertility procedures, extended hospital stays, screenings for substance use, and severe mental illness.

Key Points: 
  • Prudential Financial, Inc. ( NYSE: PRU ) has introduced new voluntary workplace insurance offerings that help support family building and mental health, including benefits that cover fertility procedures, extended hospital stays, screenings for substance use, and severe mental illness.
  • View the full release here: https://www.businesswire.com/news/home/20240404432800/en/
    Jess Gillespie, Head of Product and Underwriting, Prudential Group Insurance (Photo: Business Wire)
    Voluntary or supplemental insurance refers to optional, employee-paid benefits that can help pay for out-of-pocket medical expenses not covered by health insurance, such as co-pays, co-insurance and deductibles.
  • As part of Prudential Group Insurance’s expanded suite of Critical Illness and Hospital Indemnity insurance, the new mental health benefits include screenings for anxiety, mood disorders and substance abuse — as well as coverage for the most diagnosed mental health conditions and severe mental illness.
  • “Employees turn to their employers for benefits that can help them during key life events,” said Gillespie.

CBIZ’s 2024 State of Health Care Report Highlights Areas of Priority for Employer Benefit Plan Sponsors

Retrieved on: 
Tuesday, April 2, 2024
Consulting, Professional Services, Managed Care, Health, General Health, Small Business, Health Insurance, Genetics, Insurance, Human Resources, Finance, Steps, Element, Diagnosis, CBZ, Organization, Family, Infertility, Talent, Communication, Health insurance

CBIZ (NYSE: CBZ), a leading national provider of insurance, financial and advisory services, released its second annual State of Health Care Report.

Key Points: 
  • CBIZ (NYSE: CBZ), a leading national provider of insurance, financial and advisory services, released its second annual State of Health Care Report.
  • The State of Health Care Report includes responses from 338 businesses, spanning more than 27 states, the majority of which have more than 100 employees.
  • The survey provides insight into employer priorities, top health plan features, and emerging mental and physical health benefit trends to watch through the remainder of 2024.
  • “The insights from our State of Health Care Report reinforce the critical link between comprehensive benefits, effective communication, and strategic cost control.

Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN

Retrieved on: 
Friday, March 29, 2024
Women, Other Communications, Baby, Maternity, Communications, Practice Management, Family, Health, Consumer, General Health, Birth, Pregnancy, Infertility, Q&A, Intrauterine device, Condom, Menstrual cycle, Sterilization, IUD, Ovulation, Research, Fertility, Pelvic inflammatory disease, Hormonal contraception, Tubing (recreation), STI, Woman, USB On-The-Go, Birth control

In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.

Key Points: 
  • In a rapidly evolving landscape of reproductive health, navigating the variety of birth control options can be overwhelming.
  • “When choosing a birth control method, it's essential to consider factors such as efficacy, convenience, side effects, and personal preferences.
  • Dr. Kashani sheds light on various birth control methods in the following Q&A:
    What are the different types of birth control methods available?
  • There is limited evidence to suggest that using birth control methods for an extended period negatively impacts fertility.

China In-Vitro Fertilization Market Research Report 2023-2030 Featuring Vitrolife, Cloudnine, Nova IVI Fertility, Monash, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
General Health, Other Health, Consumer, Health, Baby, Maternity, Consciousness, Infertility, Prevalence, IVF, Sterilization, Fertility, Fertilisation, Woman, Male, Infection, Patient safety, ICSI, Birth control

Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.

Key Points: 
  • Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market.
  • Disposable devices are predicted to be among the instruments used considerably in the China In-Vitro Fertilization (IVF) market.
  • ICSI IVF is foreseen to be among the considerably utilized processes in the China In-Vitro Fertilization (IVF) market.
  • Fertility clinics are projected to experience a considerable increase in utilization in the China In-Vitro Fertilization (IVF) market.